Multiple MyelomaMyeloma ProteinsBoronic AcidsPyrazinesThalidomidePlasma CellsMelphalanParaproteinemiasKidney TransplantationMonoclonal Gammopathy of Undetermined SignificanceTransplantation, AutologousLeukemia, Plasma CellPlasmacytomaDexamethasoneTransplantsSyndecan-1Hematopoietic Stem Cell TransplantationTransplantation, HomologousBone MarrowGraft RejectionImmunosuppressive AgentsGraft SurvivalTreatment OutcomeAntineoplastic AgentsCell Line, TumorBence Jones ProteinHeart TransplantationAntineoplastic Combined Chemotherapy ProtocolsParaproteinsImmunoglobulin Light ChainsTissue DonorsTransplantationBone Marrow TransplantationProteasome InhibitorsRetrospective StudiesTime FactorsBone DiseasesOsteolysisLung TransplantationPrognosisInterleukin-6RecurrenceApoptosisStem Cell TransplantationMice, SCIDBone Marrow CellsSurvival RateSurvival AnalysisPrednisoneWaldenstrom MacroglobulinemiaChromosomes, Human, Pair 14Tumor Cells, CulturedImmunoglobulin kappa-ChainsDiphosphonatesVincristineTransplantation ConditioningSyndecansAntineoplastic Agents, AlkylatingCombined Modality TherapyMaintenance ChemotherapyTissue and Organ ProcurementImmunoglobulin lambda-ChainsCyclosporineCyclophosphamideDrug Resistance, NeoplasmDoxorubicinRemission InductionTranslocation, GeneticDisease-Free SurvivalFollow-Up StudiesHematologic NeoplasmsFlow CytometryGene Expression Regulation, NeoplasticTacrolimusSalvage TherapyDisease ProgressionCell ProliferationGraft vs Host DiseaseLiving DonorsStromal CellsRisk FactorsAmyloidosisAntibodies, MonoclonalPeripheral Blood Stem Cell TransplantationImmunosuppressionProtease InhibitorsPostoperative ComplicationsWaiting Listsbeta 2-MicroglobulinFatal OutcomeCell SurvivalImmunologic FactorsBone Marrow ExaminationChromosomes, Human, Pair 13HypergammaglobulinemiaLeukemiaHematopoietic Stem Cell MobilizationReceptors, Interleukin-6Histocompatibility TestingIn Situ Hybridization, Fluorescence